Table 2 Meta-analysis: HR value in NSCLC subgroups according to histology, stage

From: Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results

 

Nb

Patients

χ 2 heterogeneity test

Random effects HR (95% CI)

Overall

10

1236

P =0.000001

1.39 (0.97–1.99)

Stage I disease

6

554

P =0.04

1.64 (1.21–2.24)

Adenocarcinoma

5

402

P =0.000001

1.35 (0.62–2.95)

IHC

6

833

P =0.00001

1.06 (0.64–1.77)

RT–PCR

2

149

P=0.1

3.15 (1.08–9.21)

ISH

2

254

P=0.18

1.40 (0.94–2.07)

RT–PCR + ISH

4

403

P =0.03

1.31 (0.97–1.76)

  1. Abbreviations: HR, hazard ratio; IHC, immunohistochemistry; ISH, in situ hybridisation; Nb, number of studies; RT–PCR, reverse transcriptase–polymerase chain reaction.
  2. Statistically significant results are in bold.
Back to article page